Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer – real-world single-centre data

Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer – real-world single-centre data

Background and purpose: The randomised clinical trial KEYNOTE-048 has demonstrated a significant increase in survival for patients with head and neck cancer treated with pembrolizumab with or without chemotherapy. The purpose of the present retrospective study was to investigate whether survival in...

Full description

Saved in:
Bibliographic Details
Main Authors: Bogdana Patachi, Kristian H. Jensen, Anita Gothelf, Mogens Bernsdorf, Jeppe Friborg, Claus A. Kristensen
Format: Article
Language:English
Published: Medical Journals Sweden 2025-01-01
Series:Acta Oncologica
Subjects:
Immunotherapy
Head and neck cancer
Real-world data
Online Access:https://medicaljournalssweden.se/actaoncologica/article/view/42128
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items